You are here: Industry Insights > Camostat

News List

Camostat cuts recovery time in half for mild COVID-19 patients europeanpharmaceuticalreview
August 02, 2021
Phase II trial results suggest Daewoong Pharmaceutical’s Foistar (Camostat mesilate) may significantly expedite recovery from mild COVID-19 symptoms.
Daewoong Pharmaceutical Announces Camostat Achieving 50% Faster Recovery Time for Mild COVID-19 Patients Over Age of 50 in Topline Results from Phase 2B Clinical Trial prnasia
July 29, 2021
Daewoong Pharmaceutical (CEO Sengho Jeon) announced its phase 2B clinical trial topline results for Foistar (Camostat mesilate), which is being developed as a treatment for COVID-19.
Sagent Begins NIAID-Sponsored Study Investigating Outpatient COVID-19 Treatments americanpharmaceuticalreview
February 18, 2021
Sagent Pharmaceuticals announced Camostat mesilate, is one of four therapies being added to the existing ACTIV-2 Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID), which was launched by the National Institutes of Health ...
Sagent Pharmaceuticals launches phase 2 trial to evaluate Camostat Mesilate for Covid-19 treatment pharmaceutical-business-review
November 17, 2020
Sagent Pharmaceuticals announced that it has launched its Phase 2 CAMELOT trial to evaluate the safety and efficacy of Camostat Mesilate (Camostat) for the treatment of Covid-19 in high-risk outpatients and has begun enrolling patients.
German researchers identify potential drug for Covid-19 pharmaceutical-technology
March 09, 2020
Scientists at the German Primate Center – Leibniz Institute for Primate Research have found that an existing drug may help treat Covid-19.